Clinical trials: Allograft Rejection
Kidney Transplant; Complications, Kidney Transplant Rejection
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
The optimal timing for immunosuppression tapering for patients with failed kidney transplant is not known. This pilot study would be to correlate rise in cf-DNA and increase in cPRA.
- Conditions
- Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure
- Trial name
- NCT04560582
- Testing
- Blood Draw
- Where
- United States
- Sponsor
- University of Minnesota
Cardiac Allograft Vasculopathy, Heart Transplant Rejection
Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy
Heart transplantation is a golden standard for the treatment of terminal heart failure. The major cause of death in late posttransplant period is cardiac allograft vasculopathy (CAV).
- Trial name
- ECP-OCT (NCT04226521)
- Testing
- Extracoropreal photopheresis
- Where
- Croatia
- Volunteers
- 38 people
- Sponsor
- Bosko Skoric
Lung Transplantation, Chronic Lung Allograft Dysfunction
Lung Clearance Index and Lung Allograft Dysfunction
The aim of this project is to evaluate the ability of the lung clearance index (LCI) to detect early chronic lung allograft failure (CLAD) in adult lung transplant recipients over a period of 3 years.
- Conditions
- Lung Transplantation, Chronic Lung Allograft Dysfunction, Rejection Lung Transplant
- Trial name
- NCT03850002
- Testing
- Early detection of CLAD by Lung Clearance Index (LCI)
- Sponsor
- University of Zurich
Kidney Transplantation
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00263328
- Testing
- Tacrolimus, CP-690,550
- Where
- 27 sites in United States
- Volunteers
- 46 people
- Sponsor
- Pfizer
Bronchiolitis Obliterans
Immune Mechanisms of Rejection in Human Lung Allografts
The investigators have obtained compelling evidence that the development of anti-human leukocyte antigen (anti-HLA) antibodies against mismatched donor antigens significantly correlates with the development of bronchiolitis…
- Trial name
- NCT00861900
- Volunteers
- 778 people
- Sponsor
- Washington University School of Medicine
Renal Transplant Rejection, Pediatric Kidney Disease
VIRTUUS Children's Study
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.
- Conditions
- Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy
- Trial name
- VIRTUUS (NCT03719339)
- Where
- 13 sites in United States, Canada
- Volunteers
- 445 people
- Sponsor
- Children's Hospital of Philadelphia
Transplant Rejection, Allograft Rejection
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis…
- Conditions
- Transplant Rejection, Allograft Rejection, Complications
- Trial name
- SPARO (NCT03984747)
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Natera, Inc.
Heart Transplant Failure and Rejection
Allograft Dysfunction in Heart Transplant
The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
- Trial name
- NCT03102125
- Testing
- Regadenoson
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Paul Kim
End-Stage Renal Disease, End Stage Renal Disease on Dialysis
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection.
- Conditions
- End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
- Trial name
- NCT07053462
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Renal Transplant Rejection
Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
The goal of this study is to evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantation.
- Trial name
- NCT00658073
- Testing
- Kidney transplantation with MSCs infusion, kidney transplantation without MSC infusion
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Fuzhou General Hospital
Renal Transplant Rejection, Immunosuppression
Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
Currently, acute kidney injury is diagnosed by increased serum creatinine. However, creatinine is not a reliable marker for acute changes in renal function.
- Trial name
- NCT01239472
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Andre Barreto Pereira
Kidney Transplant Rejection
PROACT Pilot Trial
Kidney transplantation is considered the best option to treat end-stage kidney disease, but the recipient's immune system may respond with rejection to the transplanted organ, leading to permanent kidney damage and failure.
- Trial name
- NCT06564649
- Testing
- CXCL10 Monitoring at clinical frequency
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Kidney Transplantation, Renal Transplantation
Tolerance by Engaging Antigen During Cellular Homeostasis
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ.
- Conditions
- Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
- Trial name
- TEACH (NCT03504241)
- Testing
- Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Failure
Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
- Trial name
- NCT01666951
- Testing
- LCP-Tacro tablets, Prograf
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Veloxis Pharmaceuticals
Renal Transplantation, Graft Rejection
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.
- Trial name
- NCT00089947
- Testing
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Genzyme, a Sanofi Company
Transplant; Failure, Heart, Cardiac Allograft Vasculopathy
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
The goal of this clinical trial is to test if SGLT2 inhibitors could prevent or delay the development of Cardiac Allograft Vasculopathy (CAV) post-heart transplantation (TxC).
- Conditions
- Transplant; Failure, Heart, Cardiac Allograft Vasculopathy, Rejection Heart Transplant
- Trial name
- NCT06147271
- Testing
- SGLT2i
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Universidade Federal do Ceara
Lung Transplant
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy…
- Trial name
- CLAD (NCT06476132)
- Testing
- Belumosudil
- Where
- 12 sites in United States, Canada
- Volunteers
- 234 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Rejection Transplant
Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study
Children with kidney failure have markedly increased mortality and face repeated transplantation over their lifetime due to limited allograft half-life (12-15 years).
- Trial name
- NCT07091214
- Where
- France
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Trajectories of FEV1 After Lung Transplantation
For individuals with ESLD, lung transplantation is the best, or only treatment option with increased pulmonary function and quality of life.
- Trial name
- TRAJLUNG (NCT05934617)
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Kidney Diseases
A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection
To evaluate the clinical safety of different doses of MEDI-507 through day 33.
- Trial name
- NCT00807794
- Testing
- MEDI-507
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- MedImmune LLC